EUVIMEDEUVIMED entdecken
Übersichtsarbeit

NIMA-related Kinase 2: A master regulator of mitotic fidelity and chromosomal instability in cancer: From mechanisms to therapeutic targeting

Yashfeen Munib Siddiqui, Ilma Shakeel, Gulam Mustafa Hasan, Md Imtaiyaz Hassan

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026

DOI: 10.1016/j.bbcan.2025.189523 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026. Verfasst von Yashfeen Munib Siddiqui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences, Jamia Millia Islamia, New Delhi 110025, India. Hauptthemen laut MEDLINE: NIMA-Related Kinases, Neoplasms, Chromosomal Instability, Mitosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 248 Literaturangaben. Gefördert von: Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy, CSIR - Human Resource Development Group, Council of Scientific and Industrial Research, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NEK2 (NIMA-Related Kinase 2), a serine/threonine kinase, is a pivotal kinase for centrosome separation and mitotic fidelity. It is increasingly recognized as a driver of oncogenesis and a contributor to therapeutic resistance. This review comprehensively discusses the structural features, expression patterns, and multilayered regulation of NEK2, along with its interactions with signaling molecules, its function, and an in-depth investigation of its roles in various diseases, specifically different types of cancers. It further highlights NEK2's involvement in signaling pathways, its contribution to chromosomal instability and tumor progression, and its potential as both a biomarker and therapeutic target in cancer. Dysregulated NEK2 causes chromosomal instability, metastatic progression, and immune evasion across diverse cancers by disrupting centrosome dynamics, rewiring oncogenic pathways (e.g., PI3K-AKT, Wnt/β-catenin), and inactivating tumor suppressors such as p53. Overexpression of NEK2 correlates with poor prognosis and chemoresistance in haematological and solid tumors, suggesting its role as a biomarker and therapeutic target. Apart from its role in cancer, dysfunction of NEK2 contributes to polycystic kidney disease, bone remodeling, and immune dysregulation, highlighting its pleiotropic roles. Recent advances in targeting NEK2 include covalent inhibitors (e.g., JH295), Hec1 disruptors (e.g., INH154), and clinical-stage compounds (e.g., T-1101), alongside emerging strategies such as PROTACs and immunotherapy. However, challenges remain in developing selective, clinically viable agents. This review provides details on the molecular architecture of NEK2, disease mechanisms, and therapeutic potential, framing it as a dual regulator and guardian of mitosis that has become a rogue oncogene and advocating its exploitation in translational medicine across cancer and non-cancer pathologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NIMA-Related KinasesNeoplasmsChromosomal InstabilityMitosisHumansSignal TransductionAnimalsMolecular Targeted TherapyBiomarkers, Tumor

Stichwörter der Autor:innen

BiomarkersCancer signalingCell cycle regulationCentrosome separationKinase inhibitorsTherapeutic targeting

Substanzen

NIMA-Related KinasesNEK2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biosciences, Jamia Millia Islamia, New Delhi 110025, India.
  • Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, India.
  • Department of Basic Medical Science, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
  • Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi 110025, India. Electronic address: mihassan@jmi.ac.in.

Förderung

  • Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy
  • CSIR - Human Resource Development Group
  • Council of Scientific and Industrial Research, India
  • Central Council for Research in Unani Medicine

Zitieren

APA

Siddiqui, Y. M., Shakeel, I., Hasan, G. M., & Hassan, M. I. (2026). NIMA-related Kinase 2: A master regulator of mitotic fidelity and chromosomal instability in cancer: From mechanisms to therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189523

Vancouver

Siddiqui YM, Shakeel I, Hasan GM, Hassan MI. NIMA-related Kinase 2: A master regulator of mitotic fidelity and chromosomal instability in cancer: From mechanisms to therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026. doi:10.1016/j.bbcan.2025.189523

BibTeX
@article{Siddiqui2026,
  author = {Siddiqui, Yashfeen Munib and Shakeel, Ilma and Hasan, Gulam Mustafa and Hassan, Md Imtaiyaz},
  title = {NIMA-related Kinase 2: A master regulator of mitotic fidelity and chromosomal instability in cancer: From mechanisms to therapeutic targeting},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2026},
  doi = {10.1016/j.bbcan.2025.189523}
}
Kostenlos starten →